Breaking Down the Headlines: Addressing the Buzz Around Incretin-Based Therapies With Patients

Previous Episode: How to Implement Earlier Hepatitis B and Hepatitis Delta Screening

Next Episode: The Art of Multidisciplinary Care for Patients With Metabolic Dysfunction–Associated Steatohepatitis

In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:

Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability

Presenters:

Jennifer Green, MD
Professor of Medicine
Division of Endocrinology and Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Carol Hatch Wysham, MD
Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Link to online program:
https://bit.ly/48b6XnW

Breaking Down the Headlines: Addressing the Buzz Around Incretin-Based Therapies With Patients

CCO Medical Specialties Podcast